NCT03994263 is a NA clinical trial of ITind device implant in BPH, sponsored by Medi-Tate Ltd..

Who is sponsoring NCT03994263?

NCT03994263 is sponsored by Medi-Tate Ltd..

What drugs are being tested in NCT03994263?

Interventions in NCT03994263: ITind device implant.

Is NCT03994263 still recruiting?

NCT03994263 is currently terminated. Last updated 7 October 2021.

Last reviewed 2021-10-07 · How we verify

NCT03994263

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI

Terminated NA Last updated 7 October 2021

What this trial tests

NA trial testing ITind device implant in BPH in 1 participant. Terminated before completion.

Timeline

18 November 2019

Primary endpoint
18 February 2021

18 February 2021

Quick facts

Lead sponsor	Medi-Tate Ltd.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	18 November 2019
Primary completion	18 February 2021
Estimated completion	18 February 2021
Sites	1 location across Germany

Drugs / interventions tested

ITind device implant

Conditions studied

BPH — all drugs for BPH →

Sponsor

Medi-Tate Ltd.

Who can join

40 and older, male only, with BPH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of up to 15 eligible subjects will be enrolled into this open-labeled one-arm study designed to observe the mechanism of action of iTind when using MRI

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

iTIND: the second-generation temporary implantable nitinol device for minimally invasive treatment of benign prostatic hyperplasia.
Balakrishnan D, Jones P, Somani BK. · · 2020 · cited 11× · PMID 32655690 · DOI 10.1177/1756287220934355

Verify or expand the search:

Other recruiting trials for BPH

Currently open trials in the same condition.

NCT07115147 — Blue Diode Laser Vaporization for BPH · NA · recruiting
NCT05401032 — Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH. · Phase 2 · recruiting
NCT05719220 — Effect of Group Preoperative Pelvic Floor Training for HoLEP · recruiting
NCT05620784 — Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP · Phase 3 · recruiting
NCT05330520 — Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Pat · NA · recruiting

Other Medi-Tate Ltd. trials

Trials by the same sponsor.

NCT04579913 — A Multi-center, International Prospective Follow up Study · terminated
NCT03239951 — Study to Assess the Efficacy, Safety and Tolerability of (iTind) · NA · terminated
NCT03395522 — Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03994263 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medi-Tate Ltd.
Last refreshed: 7 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03994263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing